Since our inception, we have been strategically building out manufacturing facilities according to GMP standard. Our manufacturing efficiencies in producing biologic drugs endorses our capabilities of offering world-class therapies to the patients in a quality and affordable fashion.
Zhangjiang, ShangHai
We possess the know-hows of both commercial-scale and trial material manufacturing, and most of our Phase 1/2 clinical trial materials have been manufactured at our existing clinical facilities in Shanghai. Batches produced at this site are also planned to be used for IND filings by our customers with the FDA.
Yuxi, YunNan
Our manufacturing facilities in Yuxi, Yunnan are commercialization-ready and satisfy the product validation prerequisite for the approval of innovative drug candidates under current regulations in China. The concentrated fed-batch or perfusion technologies used at our Yuxi facilities allow us to generate higher titer and yield than the conventional fed-batch technology, driving the high-end of the industry range. We expect the current capacities of our Yuxi facilities will support our commercial manufacturing needs in the near future.
Zhangjiang, ShangHai
We possess the know-hows of both commercial-scale and trial material manufacturing, and most of our Phase 1/2 clinical trial materials have been manufactured at our existing clinical facilities in Shanghai. Batches produced at this site are also planned to be used for IND filings by our customers with the FDA.
Yuxi, YunNan
Our manufacturing facilities in Yuxi, Yunnan are commercialization-ready and satisfy the product validation prerequisite for the approval of innovative drug candidates under current regulations in China. The concentrated fed-batch or perfusion technologies used at our Yuxi facilities allow us to generate higher titer and yield than the conventional fed-batch technology, driving the high-end of the industry range. We expect the current capacities of our Yuxi facilities will support our commercial manufacturing needs in the near future.